For research and educational purposes only. Not intended for human consumption.
BPC-157
Extensively Studied- •2024-2025 GI healing and IBD research
- •WADA prohibited since 2022 (S0 category)
- •Oral vs injectable bioavailability studies
Body Protection Compound-157 | Pentadecapeptide
Overview
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a protective protein found in human gastric juice. It's known for its remarkable healing properties and is extensively researched for tissue repair, inflammation reduction, and gastrointestinal protection. Not FDA approved and prohibited by WADA (added 2022) under S0: Non-Approved Substances. Banned by WADA
Key Benefits
Accelerated healing of tendons, ligaments, muscles, bones, and localized tissue repair. Superior bioavailability for targeted healing with anti-inflammatory effects.
Mechanism of Action
Injectable BPC-157 provides direct tissue targeting and higher local concentrations. Promotes angiogenesis (formation of new blood vessels), enhances collagen synthesis, modulates growth factor expression, and provides localized protection against tissue damage.
Molecular Information
Pharmacokinetics
Research Indications
Tendon Healing
Accelerated tendon-to-bone healing and improved biomechanical properties in injury models. Most effective with localized injection.
Muscle Recovery
Enhanced muscle healing and reduced recovery time following crush injuries and surgical procedures with direct tissue targeting.
Angiogenesis
Promotes blood vessel formation and improves vascularization in healing tissues through localized delivery.
Research Protocols
Disclaimer: Commonly cycled 4-12 weeks on, 4+ weeks off in research protocols. No loading phase is typically used. Tapering is generally not reported as necessary, though some gradually reduce over the final week on longer cycles. This is not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Tendon/Joint healing | 250-500mcg | 1-2x daily | SubQ near injury |
| Serious injury | 500-1000mcg | 2x daily | SubQ near injury |
| General healing | 250-500mcg | 1-2x daily | SubQ or IM |
| Maintenance | 250mcg | 1x daily | SubQ |
Timing: Injectable BPC-157 is most effective on empty stomach. For injury healing, inject as close to the injury site as possible (subcutaneous). Rotate injection sites to prevent tissue irritation.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean work area and hands thoroughly
Calculate required BAC water volume using calculator below
Draw BAC water into syringe
Inject slowly down vial side (not directly onto powder)
Gently swirl until dissolved (never shake)
Store in refrigerator, use within 28 days
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
White, Fluffy Cake
Lyophilized powder should appear as a white, fluffy "cake" that fills most of the vial bottom. This indicates proper freeze-drying.
Clear Solution After Reconstitution
When properly mixed with BAC water, solution should be crystal clear with no particles or cloudiness.
Slight Clumping
Small clumps that dissolve completely with gentle swirling are acceptable. Shipping can cause minor compaction.
Collapsed or Melted Appearance
If powder appears collapsed, melted, or stuck to vial sides, it may have been exposed to heat during shipping.
Cloudy After Reconstitution
Persistent cloudiness, particles, or precipitates after gentle mixing indicate degraded or contaminated peptide.
What to Expect
- •Week 1-2: Reduced inflammation and pain at injection site
- •Week 2-4: Improved healing rate and tissue repair
- •Week 4-8: Maximum localized healing benefits
- •Side effects: Mild injection site redness or irritation
- •Most effective for: Tendon, ligament, muscle injuries
Side Effects & Safety
Side Effects
- •May cause mild injection site reactions
- •Consult doctor if on blood thinners due to angiogenesis effects
- •Not recommended during pregnancy or breastfeeding
- •WADA prohibited (S0: Non-Approved Substances) - not for competitive athletes
When to Stop
- •Signs of infection at injection site
- •Severe allergic reactions
- •Unusual swelling or bleeding
- •Any concerning symptoms
- •Consult healthcare provider
References
5 Studies2025 Human IV Pilot Study
Humans | 2 adults | IV up to 20mg | Well tolerated, no adverse events
First IV human pilot study showing BPC-157 was well tolerated with no clinically meaningful changes in vital signs, ECG, or laboratory biomarkers. Plasma levels returned to baseline within 24h.
View StudyChronic Knee Pain Study
Humans | 12 patients | Single injection | 7/12 relief >6 months
Retrospective study showing 7 out of 12 people with chronic knee pain experienced relief lasting over six months after one BPC-157 injection.
2024 Systematic Review
Meta-analysis | 36 studies (1993-2024) | 35 preclinical, 1 clinical
Comprehensive review showing BPC-157 enhances growth hormone receptor expression and pathways involved in cell growth and angiogenesis while reducing inflammatory cytokines.
Quick Start Guide
Research Disclaimer
BPC-157 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving BPC-157 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of BPC-157 for any purpose. Consult qualified professionals for any research applications.